Prior Authorization Recommended

Prior authorization is recommended for high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HDC‑AHSCT). Providers should submit a prior authorization request with supporting clinical documentation described below. Absent plan-specific prior‑auth criteria at the code level, follow the Clinical Policy Bulletin and member plan provisions for authorization requirements.

• Prior authorization recommended for HDC‑AHSCT
• If performed within an NCI- or FDA‑sponsored clinical trial, document trial sponsorship/authorization

Experimental / Investigational Exclusion

Aetna considers autologous, tandem, and allogeneic hematopoietic cell transplantation for breast cancer experimental and investigational except when performed in an NCI- or FDA‑sponsored clinical trial or when coverage is otherwise required by state mandate or plan provisions. Requests for these procedures outside those exceptions are subject to denial.

• Autologous hematopoietic cell transplantation — experimental/investigational for breast cancer
• Tandem hematopoietic cell transplantation — experimental/investigational for breast cancer
• Allogeneic hematopoietic cell transplantation — experimental/investigational for breast cancer
• Exception: covered when performed in an NCI- or FDA‑sponsored clinical trial or by applicable mandate

Evidence-based Denial Risk

High-quality evidence (including randomized controlled trials and a Cochrane review) has shown increased treatment‑related mortality and little or no overall survival benefit for HDC with autologous grafting in early poor‑prognosis breast cancer. Providers should expect a high risk of medical necessity denial when clinical documentation does not demonstrate trial enrollment or compelling, case-specific rationale.

• Randomized trials and Cochrane review report increased transplant‑related mortality (TRM) and no clear OS benefit
• Bezwoda trial concerns noted — data integrity issues

Coding and Billing Documentation

Maintain complete coding and billing documentation for transplantation services. Include all relevant CPT, HCPCS and ICD‑10 procedure and diagnosis codes that describe the transplant type and underlying breast cancer diagnosis.

• Document CPT codes for harvesting and transplantation (e.g., 38205, 38206, 38230, 38241) as applicable
• Include HCPCS S2150 when used and map claims to the appropriate global definition
• Include ICD‑10 diagnosis codes for breast malignancy or in situ disease (e.g., C50.x, D05.x, C79.81)

Required Supporting Documentation

Providers must include required supporting documentation with prior authorization or coverage exception requests. At minimum, submit pathology and staging details, tumor subtype (ER/PR/HER2), number of positive lymph nodes, prior therapies (surgery, radiation, chemotherapy, hormonal therapy), performance status, transplant regimen, and evidence of enrollment in an NCI‑ or FDA‑sponsored clinical trial when applicable.

• Tumor subtype (ER/PR/HER2) and node status
• Prior systemic and local therapies and dates
• Performance status and comorbidities
• Transplant regimen and source of stem cells
• Clinical trial protocol identifier and documentation of sponsorship/authorization (if applicable)

Stepwise Treatment Before Transplant

Follow a stepwise approach before considering transplantation for breast cancer. Standard therapies — surgery, standard‑dose chemotherapy, radiation, and hormonal therapy where indicated — should be considered and documented. Enrollment in clinical trials is encouraged prior to pursuing experimental transplant approaches.

• Document prior standard‑dose chemotherapy, surgery, radiation, and hormonal therapy where applicable
• Consider and document clinical trial enrollment or why trial participation was not feasible

Policy History and Clinical Policy Bulletin Guidance

Follow the Aetna Clinical Policy Bulletin and the plan’s specific provisions for documentation retention and code‑level prior authorization rules. The Policy History and Clinical Policy Bulletin notes provide the effective date and last review; absence of explicit criteria at the code level may affect adjudication — consult plan‑specific rules.

• Refer to the Clinical Policy Bulletin Notes for plan interpretation and operational details
• Effective date: 2001-06-12; Last review: 07/18/2023; Next review: 05/23/2024

Document staging and receipt of standard treatments before transplant consideration

Document standard staging and evaluations prior to transplant consideration, including results of surgery, imaging/staging workup, and receipt of standard‑dose chemotherapy, radiation, or hormonal therapy as clinically indicated.

• Standard staging and evaluation results
• Evidence of prior standard therapies (surgery, chemo, radiation, hormonal)

Assess and record performance status, prior treatments, donor availability, and chemo‑sensitivity

Assess and document performance status, prior systemic treatments and responses, donor availability for allogeneic transplant, and evidence of disease sensitivity to chemotherapy; record whether reduced‑intensity conditioning (RIC) was considered for fragility/poor performance status.

• Performance status and pre‑transplant comorbidities
• Prior chemotherapy regimens and response (chemo‑sensitivity)
• Donor availability and HLA status for alloHSCT
• Consideration of RIC vs myeloablative conditioning

Perform transplants at specialized centers with appropriate expertise and reporting (implied)

Specialized transplant center requirements are not specified in this Clinical Policy Bulletin; however, registry reports and trial settings imply procedures are performed at centers with appropriate transplant expertise and reporting systems.